Cooperative Agreement 2537984
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
San Diego, CA 92101, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project will utilize a novel technology to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ a machine...
- Federal Cooperative Agreement Summary Nexgen Cancer Detection LLC received a $1.25M Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded June 15, 2025, with completion targeted for May 31, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project to develop and validate an enriched cancer DNA detection technology for improved cancer diagnostics from blood samples. The...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
- The National Cancer Institute awarded Senticell LLC $399,995 for a Phase I Small Business Technology Transfer (STTR) project grant on September 1, 2026, to develop an red blood cell–based liquid biopsy platform for detecting circulating tumor DNA in early-stage non-small cell lung cancer. The recipient will establish the biological and clinical performance of RBC-bound tumor DNA detection using vertebrate animal models of KRAS- and EGFR-driven lung cancer to characterize in vivo kinetics of...
- The National Science Foundation awarded Rumedical Nova LIMITED Liability Company $305,000 on July 15, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to design and validate a compact chip-based platform for detecting lung cancer biomarkers in blood serum with high sensitivity and speed. The research will focus on developing an innovative nanoscale sensing element capable of recognizing disease signals at extremely low concentrations in a rapid, sensitive, and...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...
- The National Institute of General Medical Sciences awarded Everest Biolabs, Inc. $1,153,043 under the Small Business Innovation Research Program (CFDA 93.859, Biomedical Research and Research Training) on September 1, 2026, to develop plate-based methods and materials for isolating extracellular vesicles from biofluids using dual-mode chromatography combining size exclusion chromatography with affinity-based depletion of common contaminants. The project will deliver high-performance,...
- The National Science Foundation awarded a $1.25 million Cooperative Agreement to Cerflux Inc. on August 1, 2026, under the SBIR Phase II program (CFDA 47.084, NSF Technology, Innovation, and Partnerships). Cerflux will develop a scalable ex vivo testing platform built on three-dimensional tissue engineering to screen anticancer agents against solid tumors. The platform recreates key structural and biological features of tumor tissue outside the body for quantitative drug response testing....
- The National Cancer Institute awarded Vivid Bioinnovations, PBC $306,872 on August 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop CAGES (Cell Assemblies in Gel Enclosures), an ultrahigh-throughput platform for screening chimeric antigen receptor T-cell (CAR-T) therapies. The platform encapsulates millions of defined CAR-T and cancer cell interactions in biocompatible gel shells, enabling parallel assay of multi-day co-cultures with direct...
- Federal Grant Award Summary Avant Genomics, Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I project grant from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded October 1, 2025, with a completion date of September 30, 2026. The company is developing an automated microfluidic-based system that streamlines bisulfite conversion, a critical and time-consuming step in preparing circulating tumor DNA...